Its hard to imagine that in such a short statement someone can reveal such an incredible level of ignorance.... he's wrong on so many levels.
caught bits of the call...
incredible organic growth
the symphony and qiaexcel should be huge...the former could be front end for hc2 but requires pma etc
qiacube has been a blockbuster
qiagen has decided to continue the IP litigation with TWTI (appeal?)...sounds like moving to higher court
300 or so bps of operating margin improvement expected...
re: hpv biz in europe he used the word "crescendo" to describe the next couple of years
as far as the ex-digene biz it looks like the platforms they are putting in labs are so flexible that it will create huge annuities on the consumables end...
look forward to the analyst day for some more details
Good post and well said. That about sums it up. If we get a significant recession, even higher oil, adverse geo-military events, etc., etc., one will be even more pleased to be in this vs other go-go sectors.
this is such a solid company with so many hidden assets not to mention those that are visible including their worldwide presence and channel (and relationships)...definitely just need to settle back and buy the dips and take some off when it runs if that's your style...otherwise i think you can relax and count on 20-30% yearly gains in the stock price for a while, if not more depending on the pipeline and hpv growth (which i think they are understating)...end of fy08 it wouldn't surprise me to see revs and earnings significantly higher than current guidance...it's not the explosive stock price movement one might have gotten on a smaller share base (emphasis on might) but i don't see them down 80% either!
lotta worse places to stick your dough....stock is up year-to-date which is an elite crowd...
surprisingly light volume on the dax...be interesting to see how it trades here
Maybe a MERK or Roche will realize they could get a great growth engine in the future of medicine really cheap. Or mabe somebody we did not think of. After-all qgen was never on our radar in the old Digene days.
40% rev growth and 30% eps growth give or take is pretty hard to find in this market...esp since they are less economically sensitive than most companies (though not completely)
seems cheap to me at 21 ... not to mention this mgmt deserves a premium multiple for reliability...
if vmsi can get taken out at 11x sales then qiagen at 4-5x forward sales, and less than 30x forward earnings seems pretty reasonable!
what a change, eh?
certainly looks solid at first glance...looks like rev guidance is more or less in-line with that range that encompasses consensus (with room to grow) and eps guidance for 2008 is well above consensus...
will take a closer look at the details and call tomorrow but seems just fine on the headline numbers
seems the estimates for revs for 2008 has crept up to 892 per yahoo...pretty big number with some room for disappointment on full year guidance imho but we'll see...
first call has this quarter at 199.6 and 14 cents